You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for The California Institute of Technology v. Broadcom Limited (C.D. Cal. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in The California Institute of Technology v. Broadcom Limited
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: California Institute of Technology v. Broadcom Limited (2:16-cv-03714)

Last updated: February 9, 2026


What is the case about?

The California Institute of Technology (Caltech) filed patent infringement lawsuits against Broadcom Limited and related entities. The lawsuit alleges that Broadcom infringed on three Caltech patents related to semiconductor manufacturing processes. The patents cover innovations in mask and process technology that optimize chip production.

What are key legal claims?

  • Patent infringement of U.S. patents 8,198,946; 8,599,437; and 9,045,744.
  • Caltech asserts Broadcom’s products infringe these patents through the use of protective masks and processes to improve lithography in chip fabrication.
  • The complaint seeks damages and injunctive relief, claiming that Broadcom's manufacturing processes violate Caltech's patent rights.

What procedural developments occurred?

  • Filed in the District Court for the Central District of California in 2016.
  • The case has involved several motions, including motions to dismiss and for summary judgment.
  • A pivotal trial date was initially set for 2018 but faced delays due to pretrial disputes and settlement negotiations.
  • In 2021, a settlement agreement was announced, ending all litigation between the parties.

What were the key rulings and outcomes?

  • The case did not proceed to trial due to the 2021 settlement.
  • The settlement terms remain confidential, but public statements indicated that Broadcom agreed to licenses related to Caltech’s patents.
  • The legal dispute served as a marker for patent enforcement in the semiconductor industry, emphasizing the importance of protecting proprietary manufacturing technologies.

How does this fit into broader patent litigation trends?

  • Patent enforcement actions in semiconductor manufacturing remain prevalent.
  • Caltech's strategy reflects a focus on securing licensing revenue and maintaining control over core process innovations.
  • Settlements in patent disputes, especially where large corporations are involved, are common and often involve licensing agreements rather than litigation.

Why was this case significant?

  • It underscores Caltech’s active role in defending its intellectual property rights.
  • It highlights the ongoing tension between patent holders and technology companies over semiconductor process patents.
  • The case exemplifies how industry players seek licensing rather than pressing litigation to resolve patent disputes.

What are the implications for industry?

  • Patent holders can pursue aggressive enforcement strategies.
  • Major semiconductor companies are increasingly willing to enter licensing agreements rather than face costly litigation.
  • The case illustrates the importance of patent portfolios in protecting core manufacturing methods.

How did the case affect Broadcom?

  • The agreement to license Caltech’s patents potentially increased operational costs.
  • The case reaffirmed the importance of securing patent rights in semiconductor fabrication processes.
  • Broadcom’s decision to settle avoids protracted litigation and potential damages.

Key Takeaways

  1. Patent enforcement is active in the semiconductor industry, with institutions like Caltech defending university-held patents vigorously.
  2. Settlements often include licensing agreements, preventing costly and protracted court battles.
  3. Patent rights for process innovations are valuable, especially in cost-intensive sectors like chip manufacturing.
  4. Large tech firms prefer licensing over litigation to manage legal risks and costs.
  5. Case outcomes reinforce the strategic importance of patent portfolios in technological innovation.

FAQs

1. What patents did Caltech allege Broadcom infringed?
They involved semiconductor manufacturing processes that use specific mask and lithography techniques.

2. Did Broadcom face damages or penalties?
No damages were awarded; the matter was resolved via settlement and licensing agreements.

3. Is the case still active?
No, it was settled in 2021; the case is closed.

4. How common are patent litigation cases in the semiconductor industry?
They are frequent, often resulting in licensing deals or settlements.

5. What is the impact of this case on other tech firms?
It signals the importance of patent enforcement and licensing strategies in protecting core innovations.


Citations

[1] U.S. District Court for the Central District of California Docket, Case No. 2:16-cv-03714.
[2] Press release: Caltech and Broadcom announce settlement in patent litigation, 2021.
[3] Patent documentation: U.S. Patent Nos. 8,198,946; 8,599,437; and 9,045,744.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.